The "Pharmaceutical Contract Development & Manufacturing Market by Service, End User - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report presents key industry drivers, restraints, challenges, and opportunities. The growth of the pharmaceutical contract development and manufacturing market is mainly attributed to complex manufacturing requirements, patent expiration, increasing investments in pharmaceutical R&D, the pharmaceutical industry's inclination towards cutting-edge technologies, and the outbreak of the coronavirus pandemic.

Moreover, the growing demand for cell and gene therapies and personalized medicines and the growth of the High-potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) markets offer significant opportunities for the players operating in the pharmaceutical contract development and manufacturing market.

Market Dynamics

Drivers

• Complex Manufacturing Requirements of the Pharmaceutical industry and Manufacturers' Growing inclination Toward the Use of Cutting-Edge Technologies
• Rising Demand for Generic Medicines and Biologics
• Patent Expiration
• Increasing Investments in Pharmaceutical R&D
• Outbreak of the COVID-19 Pandemic

Challenges

• Shortage of Skilled Professionals
• Introduction of Serialization

Opportunities

• Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
• Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets

Companies Mentioned

• Thermo Fisher Scientific Inc. (U.S.)
• Catalent Inc. (U.S.)
• Lonza Group Ltd (Switzerland)
• Recipharm AB (Sweden)
• Vetter Pharma International GmbH (Germany)
• Piramal Enterprises Limited (India)
• Almac Group (U.K.)
• Cambrex Corporation (U.S.)
• Samsung Biologics Co. Ltd (South Korea)
• Siegfried Holding AG (Switzerland)
• FUJIFILM Diosynth Biotechnologies (Japan)
• Aenova Group (Germany)
• C.H. Boehringer Sohn AG & Co. KG (Germany)
• Fareva SA (Luxembourg)
• Fabbrica Italiana Sintetici S.p.A. (Italy)
• WuXi Biologics (Cayman) Inc. (China)
• Aurobindo Pharma Ltd. (India)

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

• Pharmaceutical Manufacturing Services
• Pharmaceutical API Manufacturing Services
• Pharmaceutical FDF Manufacturing Services
• Parenteral/Injectable Manufacturing Services
• Tablet Manufacturing Services
• Capsule Manufacturing Services
• Oral Liquid Manufacturing Services
• Other Formulations Manufacturing Services
• Drug Development Services
• Biologics Manufacturing Services
• Biologics API Manufacturing Services
• Biologics FDF Manufacturing Services
• Packaging Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

• Large Pharmaceutical Companies
• Small and Mid-size Pharmaceutical Companies
• Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Switzerland
• Rest of Europe (RoE)
• Asia-Pacific (APAC)
• China
• Japan
• India
• Rest of APAC (RoAPAC)
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa

For more information about this report visit https://www.researchandmarkets.com/r/2pij4z

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005487/en/